T2 Biosystems IncNASDAQ:TTOONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE5.6750
- TODAY'S CHANGE (%)0.0350 (0.6206%)
- Bid / Lots5.4000/ 1
- Ask / Lots5.7200/ 2
- Open / Previous Close5.6500 / 5.6400
- Day Range
- 52 Week Range
- Volume179,724
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TTOO |
|---|---|---|
| 09:32 ET | 2269 | 5.52 |
| 09:34 ET | 300 | 5.605 |
| 09:36 ET | 400 | 5.5238 |
| 09:38 ET | 1396 | 5.47 |
| 09:39 ET | 2400 | 5.5499 |
| 09:41 ET | 1230 | 5.4801 |
| 09:45 ET | 2082 | 5.504 |
| 09:48 ET | 2800 | 5.41 |
| 09:50 ET | 3213 | 5.46 |
| 09:52 ET | 290 | 5.46 |
| 09:56 ET | 2132 | 5.41 |
| 09:57 ET | 400 | 5.4375 |
| 09:59 ET | 300 | 5.411 |
| 10:03 ET | 1189 | 5.45 |
| 10:06 ET | 10501 | 5.66 |
| 10:10 ET | 100 | 5.5001 |
| 10:12 ET | 200 | 5.599 |
| 10:17 ET | 875 | 5.6 |
| 10:19 ET | 234 | 5.59 |
| 10:24 ET | 1125 | 5.6 |
| 10:26 ET | 117 | 5.56 |
| 10:28 ET | 3798 | 5.64 |
| 10:33 ET | 100 | 5.655 |
| 10:35 ET | 465 | 5.665 |
| 10:37 ET | 5000 | 5.675 |
| 10:39 ET | 2018 | 5.72 |
| 10:42 ET | 1047 | 5.76 |
| 10:44 ET | 1217 | 5.7 |
| 10:46 ET | 300 | 5.69 |
| 10:48 ET | 2756 | 5.76 |
| 10:50 ET | 200 | 5.727 |
| 10:51 ET | 3055 | 5.66 |
| 10:53 ET | 300 | 5.65 |
| 10:55 ET | 500 | 5.67 |
| 10:57 ET | 350 | 5.6344 |
| 11:00 ET | 900 | 5.67 |
| 11:04 ET | 2005 | 5.69 |
| 11:06 ET | 543 | 5.6673 |
| 11:08 ET | 3304 | 5.6301 |
| 11:09 ET | 233 | 5.6354 |
| 11:13 ET | 120 | 5.6 |
| 11:18 ET | 1000 | 5.65 |
| 11:22 ET | 150 | 5.6427 |
| 11:24 ET | 400 | 5.64 |
| 11:26 ET | 6338 | 5.55 |
| 11:27 ET | 5033 | 5.62 |
| 11:31 ET | 1300 | 5.56 |
| 11:38 ET | 3610 | 5.5403 |
| 11:40 ET | 354 | 5.54 |
| 11:42 ET | 998 | 5.52 |
| 11:45 ET | 1648 | 5.51 |
| 11:49 ET | 100 | 5.51 |
| 11:51 ET | 400 | 5.54 |
| 11:54 ET | 100 | 5.58 |
| 11:56 ET | 770 | 5.535 |
| 12:02 ET | 1000 | 5.56 |
| 12:12 ET | 843 | 5.5101 |
| 12:18 ET | 1200 | 5.52 |
| 12:21 ET | 526 | 5.48 |
| 12:25 ET | 704 | 5.48 |
| 12:30 ET | 200 | 5.48 |
| 12:32 ET | 2189 | 5.4901 |
| 12:36 ET | 1048 | 5.45 |
| 12:39 ET | 6189 | 5.407 |
| 12:41 ET | 2300 | 5.44 |
| 12:43 ET | 300 | 5.435 |
| 12:45 ET | 903 | 5.39 |
| 12:48 ET | 368 | 5.4033 |
| 12:52 ET | 700 | 5.4177 |
| 12:54 ET | 400 | 5.425 |
| 12:56 ET | 128 | 5.425 |
| 12:57 ET | 292 | 5.4009 |
| 01:06 ET | 1300 | 5.425 |
| 01:08 ET | 200 | 5.42 |
| 01:10 ET | 890 | 5.5 |
| 01:14 ET | 150 | 5.4401 |
| 01:17 ET | 250 | 5.4674 |
| 01:19 ET | 100 | 5.48 |
| 01:21 ET | 300 | 5.52 |
| 01:24 ET | 250 | 5.47 |
| 01:32 ET | 100 | 5.46 |
| 01:33 ET | 300 | 5.52 |
| 01:35 ET | 1300 | 5.46 |
| 01:37 ET | 100 | 5.4999 |
| 01:46 ET | 3344 | 5.4 |
| 01:53 ET | 300 | 5.4101 |
| 01:55 ET | 460 | 5.404 |
| 01:57 ET | 2149 | 5.5 |
| 02:04 ET | 2494 | 5.5 |
| 02:09 ET | 250 | 5.46 |
| 02:15 ET | 500 | 5.5 |
| 02:18 ET | 226 | 5.4995 |
| 02:20 ET | 976 | 5.49 |
| 02:42 ET | 100 | 5.44 |
| 02:44 ET | 640 | 5.49 |
| 02:51 ET | 646 | 5.49 |
| 02:54 ET | 980 | 5.55 |
| 03:09 ET | 100 | 5.54 |
| 03:18 ET | 200 | 5.5 |
| 03:20 ET | 2007 | 5.55 |
| 03:21 ET | 100 | 5.58 |
| 03:23 ET | 100 | 5.59 |
| 03:27 ET | 200 | 5.5576 |
| 03:30 ET | 1585 | 5.7 |
| 03:32 ET | 342 | 5.66 |
| 03:36 ET | 550 | 5.65 |
| 03:39 ET | 1237 | 5.62 |
| 03:41 ET | 962 | 5.68 |
| 03:45 ET | 1200 | 5.7 |
| 03:48 ET | 673 | 5.67 |
| 03:50 ET | 2520 | 5.7 |
| 03:52 ET | 5067 | 5.6505 |
| 03:54 ET | 350 | 5.7 |
| 03:56 ET | 209 | 5.7104 |
| 03:57 ET | 812 | 5.7 |
| 03:59 ET | 4301 | 5.675 |
Today
May 15, 2024
DJ T2 Biosystems Up 42% After News Including Private Placement and Public Offer Withdrawal, from 2:52PM ET on Wednesday May 15, 2024 by Dow Jones
2:52PM ET on Wednesday May 15, 2024 by Dow JonesT2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules, from 7:00AM ET on Wednesday May 15, 2024 by Dow Jones
7:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
*DJ T2 Biosystems Withdraws Filing for Offering of Stock and Warrants, from 5:13PM ET on Tuesday May 14, 2024 by Dow Jones
5:13PM ET on Tuesday May 14, 2024 by Dow JonesT2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock, from 5:00PM ET on Tuesday May 14, 2024 by Dow Jones
5:00PM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
T2 Biosystems Inc | 86.7M | -0.3x | --- |
EUDA Health Holdings Ltd | 80.8M | -6.3x | --- |
Hyperfine Inc | 60.6M | -1.5x | --- |
Milestone Scientific Inc | 52.1M | -7.2x | --- |
Co-Diagnostics Inc | 35.6M | -0.8x | --- |
Vivos Inc | 73.8M | -20.6x | --- |
Company Information
T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Contact Information
- Headquarters
- 101 Hartwell AveLEXINGTON, MA, United States 02421-3125
- Phone
- 781-457-1200
- Fax
- 781-357-3080
Executives
- Chairman of the Board, President, Chief Executive Officer
- John Sperzel
- Chief Financial Officer
- John Sprague
- Senior Vice President, General Counsel
- Michael Gibbs
- Senior Vice President of Science Research and Development
- Roger Smith
- Chief Commercial Officer
- Brett Giffin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.7M |
|---|---|
Revenue (TTM) | $7.2M |
Shares Outstanding | 15.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.13 |
EPS | $-17.91 |
Book Value | $-6.91 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 12.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -676.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
